CMS Payment Experiment Strains Legal Powers, Reimbursement Norms
Executive Summary
'Perverse' new payment model for Part B drugs may test the limits of its innovation center’s waiver authority and has already drawn lawsuit threat.
You may also be interested in...
Medicare's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues
President Trump touts CMS proposal that would peg Part B prices to an international index in the hopes of lowering US costs; industry calls it foreign price controls and warns it will hinder access.
Part B's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues
President Trump touts CMS proposal that would peg Part B prices to an international index in the hopes of lowering US costs; industry calls it foreign price controls and warns it will hinder access.
Medicare Part B Demo Partially Shielded From Congress By CBO Scoring
Congressional Budget Office projects big savings from the activities of the Center for Medicare and Medicaid Innovation, making it challenging for Congress to repeal the center or interfere with certain projects.